Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of Paclitaxel-Associated Neuropathy With Fingolimod
NCT03941743Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Dec 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fingolimod in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by Mayo Clinic. Primary endpoint: Total sensory neuropathy score at 18 months. Started Dec 2019; status: completed.
02
Drugs
fingolimod
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT03941743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03941743.